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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to a 
combination of L-threonine, L-valine, L-leucine, L-isoleucine, L-lysine plus 
chromium picolinate and reduction of post-prandial glycaemic responses 
pursuant to Article 13(5) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from DoubleGood AB, submitted for authorisation of a health claim pursuant to 
Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Sweden, the EFSA Panel on 
Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation 
of a health claim related to a combination of L-threonine, L-valine, L-leucine, L-isoleucine, L-lysine plus 
chromium picolinate and reduction of post-prandial glycaemic responses. The Panel considers that the food is 
sufficiently characterised. The target population proposed by the applicant is “adults in the general population 
wishing to reduce their post-prandial blood glucose responses”. The mechanism proposed by the applicant for the 
claimed effect is “stimulating insulin release via the insulinogenic properties of the amino acids in the food”. The 
Panel notes that the evidence provided by the applicant does not establish that a reduction in post-prandial 
glycaemic responses achieved by an increase in insulin secretion is a beneficial physiological effect for the target 
population in the context of this application. The Panel considers that a cause and effect relationship has not been 
established between the consumption of the food, a combination of L-threonine, L-valine, L-leucine, L-isoleucine, 
L-lysine plus chromium picolinate, and a beneficial physiological effect for the target population. 
© European Food Safety Authority, 2014 
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SUMMARY 
Following an application from DoubleGood AB, submitted for authorisation of a health claim 
pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Sweden, 
the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion 
on the scientific substantiation of a health claim related to a combination of L-threonine, L-valine, 
L-leucine, L-isoleucine, L-lysine plus chromium picolinate and reduction of post-prandial glycaemic 
responses. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. The application included a request for the protection of proprietary data. 
The food that is the subject of the health claim is a combination of five amino acids, i.e. L-threonine, 
L-valine, L-leucine, L-isoleucine and L-lysine, plus chromium picolinate, which are dissolved in table 
water. The amounts of the single constituents, an overview of the manufacturing process and 
information on stability and batch-to-batch analyses were provided. The Panel considers that the food, 
a combination of L-threonine, L-valine, L-leucine, L-isoleucine, L-lysine plus chromium picolinate, is 
sufficiently characterised. 
The claimed effect is “reduces the post-prandial blood glucose response”. The target population 
proposed by the applicant is “adults in the general population wishing to reduce their post-prandial 
blood glucose responses”. 
Decreasing post-prandial glycaemic responses may be beneficial, for example, to individuals with 
impaired glucose tolerance, as long as post-prandial insulinaemic responses are not disproportionally 
increased. In view of the proposed mechanism, i.e. “stimulating insulin release via the insulinogenic 
properties of the amino acids in the food”, the applicant was invited to provide evidence that a 
reduction of post-prandial blood glucose responses achieved by an increase in insulin secretion is a 
beneficial physiological effect for the proposed target population. No such evidence was provided by 
the applicant. 
The Panel notes that the evidence provided by the applicant does not establish that a reduction in post-
prandial glycaemic responses achieved by an increase in insulin secretion is a beneficial physiological 
effect for the target population in the context of this application. 
The Panel considers that a cause and effect relationship has not been established between the 
consumption of the food, a combination of L-threonine, L-valine, L-leucine, L-isoleucine, L-lysine plus 
chromium picolinate, which is the subject of the health claim, and a beneficial physiological effect for 
the target population. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children’s development and health) which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the 
Community list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 10/09/2013. 
 The scope of the application was proposed to fall under a health claim based on newly 
developed scientific evidence. The application included a request for the protection of 
proprietary data. 
 On 16/10/2013, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
 On 15/01/2014, EFSA received the missing information as submitted by the applicant. 
 The scientific evaluation procedure started on 16/01/2014. 
 On 06/03/2014, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application. The clock 
was stopped on 26/03/2014 and was restarted on 10/04/2014, in compliance with 
Article 18(3) of Regulation (EC) No 1924/2006. 
 On 11/04/2014, EFSA received the requested information (which was made available to 
EFSA in electronic format on 09/04/2014). 
 During its meeting on 25/06/2014, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to a combination 
of L-threonine, L-valine, L-leucine, L-isoleucine, L-lysine plus chromium picolinate and 
reduction of post-prandial glycaemic responses. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: a combination of L-threonine, 
L-valine, L-leucine, L-isoleucine, L-lysine plus chromium picolinate and reduction of post-prandial 
glycaemic responses. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of a combination of L-threonine, L-valine, L-leucine, L-isoleucine, L-lysine plus chromium 
picolinate, a positive assessment of its safety, nor a decision on whether a combination of L-threonine, 
L-valine, L-leucine, L-isoleucine, L-lysine plus chromium picolinate is, or is not, classified as a 
foodstuff. It should be noted that such an assessment is not foreseen in the framework of Regulation 
(EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: DoubleGood AB, Scheelevägen 22, Box 719, SE-22007 Lund, 
Sweden. 
The application includes a request for the protection of proprietary data for one unpublished study 
(Svensson et al., unpublished), in accordance with Article 21 of Regulation (EC) No 1924/2006. 
Food/constituent as stated by the applicant 
According to the applicant, the food that is the subject of the health claim is a combination of five 
amino acids (i.e. L-threonine, L-valine, L-leucine, L-isoleucine and L-lysine) plus chromium picolinate, 
which are dissolved in bottled table water. In addition, for reasons of taste and preservation, the mix 
contains flavourings (e.g. lemon, pomegranate), small amounts of salt, sodium benzoate and 
potassium sorbate. The water may be carbonated. 
Health relationship as claimed by the applicant 
According to the applicant, consumption of table water containing L-threonine, L-valine, L-leucine, 
L-isoleucine, L-lysine plus chromium picolinate during a carbohydrate-rich meal reduces the post-
prandial blood glucose response without a disproportionate insulin increase. 
Concerning the proposed mechanism, the applicant argued that the amino acids might act both 
directly by stimulating insulin release via the beta cells and indirectly by stimulating incretin 
hormones (gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)) release in the 
gut. Furthermore, the applicant hypothesised that the chromium might improve insulin sensitivity, 
thereby improving the action of insulin, the secretion of which has been stimulated by the amino 
acids. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “Contributes to the reduction 
of the blood glucose rise when consumed together with a carbohydrate rich meal”. 
Specific conditions of use as proposed by the applicant 
The applicant has proposed to consume one portion, i.e. ## g of amino acids plus ## µg chromium 
picolinate, in 330 mL table water during a meal. The proposed target population is the general adult 
population wishing to reduce their post-prandial blood glucose responses. 
ASSESSMENT 
The approach used by the Panel in the evaluation of health claims is explained in the general guidance 
for stakeholders
5
. 
In assessing each specific food/health relationship that forms the basis of a health claim the Panel 
considers the extent to which:  
1. the food/constituent is defined and characterised;  
                                                     
5 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
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2. the claimed effect is defined and is a beneficial physiological effect; 
3. a cause and effect relationship is established between the consumption of the food/constituent and 
the claimed effect. 
Substantiation of the claim is dependent on a favourable outcome of the assessment of 1, 2 and 3 
above. Thus, a cause and effect relationship is considered not to be established if the outcome of any 
one of these assessments is unfavourable. 
1. Characterisation of the food/constituent 
The food that is the subject of the health claim is a combination of five amino acids, i.e. L-threonine, 
L-valine, L-leucine, L-isoleucine and L-lysine, plus chromium picolinate (CrPic), which are dissolved 
in table water. 
The amounts of the single constituents contained in one portion (330 mL) of the table water are ## g 
L-threonine, ## g L-valine, ## g L-leucine, ## g L-isoleucine, ## g L-lysine monohydrate (for a total of 
## g amino acids per portion) and ## µg CrPic (equivalent to ## µg Cr(III)). In addition, 0.033 g 
sodium chloride and 1.16 g lemon flavours are added to the water, plus the food preservatives sodium 
benzoate and potassium sorbate (0.05 g/330 mL of each). 
The indispensable amino acids L-threonine, L-valine, L-leucine, L-isoleucine and L-lysine are well-
characterised nutrients and can be measured in foods by established methods. CrPic is a compound 
derived from Cr(III) and picolinic acid. CrPic is well characterised, is authorised for use in the 
manufacture of food supplements (Annex II of Directive 2002/46/EC
6
), and can be measured in foods 
by established methods. 
An overview of the manufacturing process of the food and information on stability and batch-to-batch 
analyses were provided. 
The Panel considers that the food, a combination of L-threonine, L-valine, L-leucine, L-isoleucine, 
L-lysine plus CrPic, which is the subject of the health claim, is sufficiently characterised. 
2. Relevance of the claimed effect to human health 
The claimed effect is “reduces the post-prandial blood glucose response”. The target population 
proposed by the applicant is “adults in the general population wishing to reduce their post-prandial 
blood glucose responses”. 
The elevation of blood glucose concentrations after consumption of a food and/or meal, i.e. post-
prandial glycaemia, is a normal physiological response which varies in magnitude and duration, and 
which may be influenced by the chemical and physical nature of the food or meal consumed, as well 
as by individual factors (Venn and Green, 2007). Decreasing post-prandial glycaemic responses may 
be beneficial, for example, to individuals with impaired glucose tolerance, as long as post-prandial 
insulinaemic responses are not disproportionally increased (EFSA NDA Panel, 2012). 
The applicant indicated that the mechanism by which the food exerts the claimed effect is by 
“stimulating insulin release via the insulinogenic properties of the amino acids in the food”. In view 
of the mechanism proposed, the applicant was invited to provide evidence that a reduction in post-
prandial blood glucose responses achieved by an increase in insulin secretion is a beneficial 
                                                     
6 Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of 
the Member States relating to food supplements. OJ L 183, 12.7.2002, p. 51-57. 
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physiological effect for the proposed target population. No such evidence was provided by the 
applicant. 
The Panel notes that the evidence provided by the applicant does not establish that a reduction in post-
prandial glycaemic responses achieved by an increase in insulin secretion is a beneficial physiological 
effect for the target population in the context of this application. 
The Panel considers that a cause and effect relationship has not been established between the 
consumption of the food, a combination of L-threonine, L-valine, L-leucine, L-isoleucine, L-lysine plus 
CrPic, which is the subject of the health claim, and a beneficial physiological effect for the target 
population. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food, a combination of L-threonine, L-valine, L-leucine, L-isoleucine, L-lysine plus CrPic, 
which is the subject of the health claim, is sufficiently characterised. 
 The claimed effect is “reduces the post-prandial blood glucose response”. The target 
population proposed by the applicant is “adults in the general population wishing to reduce 
their post-prandial blood glucose responses”. The proposed mechanism by which the food 
exerts the claimed effect is by “stimulating insulin release via the insulinogenic properties of 
the amino acids in the food”. No evidence was provided that a reduction in post-prandial 
glycaemic responses achieved by an increase in insulin secretion is a beneficial physiological 
effect for the target population. 
 A cause and effect relationship has not been established between the consumption of the food, 
a combination of L-threonine, L-valine, L-leucine, L-isoleucine, L-lysine plus CrPic, and a 
beneficial physiological effect for the target population. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on a combination of L-threonine, L-valine, L-leucine, L-isoleucine, L-lysine 
plus chromium picolinate and reduction of post-prandial glycaemic responses pursuant to 
Article 13(5) of Regulation (EC) No 1924/2006 (Claim serial No: 0395_SE). September 2013. 
Submitted by DoubleGood AB. 
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